This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab in adult participants with advanced or metastatic solid tumors.
Advanced Solid Tumor, Metastatic Solid Tumor
This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab in adult participants with advanced or metastatic solid tumors.
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
-
California Cancer Associates for Research and Excellence, Encinitas, California, United States, 92024
California Cancer Associates for Research and Excellence, Fresno, California, United States, 93270
Duke University Medical Center - Duke Cancer Institute, Durham, North Carolina, United States, 27710
Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States, 19107
SCRI Oncology Partners, Nashville, Tennessee, United States, 37203
Texas Oncology - Baylor Charles A Sammons Cancer Center, Dallas, Texas, United States, 75246
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States, 77030
Virginia Cancer Specialists, Fairfax, Virginia, United States, 22031
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Jazz Pharmaceuticals,
2028-05-31